SCHEDULE 13G/A: Akram Mahesh Discloses 6.56% Passive Stake in Amneal Pharmaceuticals

Akram Mahesh has reported a beneficial ownership of 6.56% of Amneal Pharmaceuticals, Inc.'s Class A Common Stock as of March 31, 2025, through trusts managed by his wholly-owned Tattva Fiduciary Company.

Summary

• Akram Mahesh beneficially owns 20,558,759 shares of Amneal Pharmaceuticals, Inc. Class A Common Stock.
• This ownership represents 6.56% of the total 313,419,599 Class A Common Stock outstanding, as reported in the Issuer's Quarterly Report on Form 10-Q filed on May 7, 2025.
• The shares are held through various trusts (the 'Trusts') for which Tattva Fiduciary Company ('Tattva') serves as the sole trustee.
• Akram Mahesh is the sole owner of Tattva Fiduciary Company, granting him sole voting and dispositive power over these shares.
• The filing is a Schedule 13G, indicating that the shares were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Amneal Pharmaceuticals, Inc.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of a significant passive ownership stake, which is generally neutral but can be viewed as a positive signal of investor confidence due to the substantial size of the holding.

Positives

• The disclosure of a significant 6.56% passive stake by Akram Mahesh indicates a substantial, long-term investment by an individual, which can be viewed as a sign of confidence in Amneal Pharmaceuticals.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of significant ownership by an individual investor in a pharmaceutical company. It does not provide specific insights into broader industry trends or competitive dynamics within the pharmaceutical sector, as its sole purpose is to report beneficial ownership.

Related Party Transactions

• The beneficial ownership is held through certain trusts (the 'Trusts') where Tattva Fiduciary Company ('Tattva') acts as the sole trustee. Akram Mahesh is the sole owner of Tattva, establishing a related party structure for the beneficial ownership.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant passive investor's stake, which can offer some stability and confidence.
• Management: Awareness of a large, passive shareholder on the company's register.

Key Dates

Keywords

Amneal Pharmaceuticals, Akram Mahesh, Schedule 13G, Beneficial Ownership, Class A Common Stock, Pharmaceuticals, SEC Filing, Passive Investment